Skip to contentB
Benitec Biopharma Inc.
B
BNTCBenitec Biopharma Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$7.00K$7.00Kderived— vs Q4 2022 Net Income-$4.66M-$4.66MderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Benitec Biopharma Inc. · CIK 1808898 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$4,550,000N/M Operating Cash Flowderived-$4,095,000N/M Free Cash Flowderived-$4,096,000N/M Margins · derivedOperating margin-65000.0%
Net margin-66585.7%
ended Jun 30, 2023 · filed Sep 21, 2023 · 83 d after period end